Nov 24, 2021 by Patrick Bafuma and Keith SpeightsBetter Buy: Ocugen or Novavax?Will either of these hopeful vaccine makers continue to thrash the market?
Nov 13, 2021 by Patrick Bafuma and George Budwell, PhDBetter Buy: Bristol Myers Squibb vs. MerckWhich pharma giant is right for you?
Nov 13, 2021 by Patrick Bafuma and Adria CiminoPfizer: Bull vs. BearThe pharmaceutical giant has lagged the market over the past decade, but will the fight against COVID-19 change that?
Nov 10, 2021 by Patrick BafumaBig Pharma Is Going Holiday Shopping. Who's Next?After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
Nov 3, 2021 by Patrick BafumaBinge Watching Dopesick? Here Are 3 Stocks That Involve an Opioid-Free RecoveryCheck out these companies utilizing non-pharmaceutical means to optimize America's health.
Oct 27, 2021 by Patrick BafumaShould Biogen Investors Be Preparing for the Worst?With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?
Oct 26, 2021 by Patrick BafumaWas Atea Pharmaceutical's Flop Predictable?Were warning signs there for investors all along?
Oct 20, 2021 by Patrick BafumaUp Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?Codexis is leveraging its core technology to create more effective life science tools.
Oct 20, 2021 by Patrick BafumaIs This Beaten Down Biotech a Bad News Buy?It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
Oct 18, 2021 by Patrick Bafuma2 Tricks and a Treat for Gene Therapy InvestorsIt looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
Oct 8, 2021 by Patrick BafumaCan This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?This partnership is showing early efficacy in the race for an oral COVID-19 treatment, but Atea and Roche are on their haunches.
Sep 9, 2021 by Patrick BafumaThis Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.
Aug 5, 2021 by Patrick BafumaPfizer's CEO Wants to Go Shopping: 3 Potential Companies on His RadarProjecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.
Aug 4, 2021 by Patrick BafumaThis High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors MoneyAn effective oral antiviral therapy for the coronavirus may be around the corner.
Aug 3, 2021 by Patrick BafumaIs This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.
Jul 29, 2021 by Patrick BafumaThis Under-the-Radar Dementia Treatment Could Reward InvestorsWant to dabble in the market for Alzheimer's therapies but avoid Biogen? Look no further.
Jul 4, 2021 by Patrick Bafuma2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won'tAfter the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.
Jul 3, 2021 by Patrick BafumaCould This Recently IPOed Medical Device Maker Make You Rich?Small-cap epilepsy treatment specialist NeuroPace looks a lot like Abiomed did in its early days.
Jun 30, 2021 by Patrick BafumaThis Explosive Biotech Is Taking On a Huge New MarketDominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Jun 29, 2021 by Patrick BafumaWill This 2020 Biotech IPO Crush the Market This Year?Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.
